Real-World check: Talzenna's safety under the microscope in korea

NCT ID NCT04982848

Not yet recruiting Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 11, 2026 · Updated 24 times

Summary

This study tracks 600 people in Korea with advanced breast cancer and a BRCA gene mutation who are prescribed Talzenna. Researchers will watch for side effects and how well the drug works in real-life medical practice, not in a controlled experiment. The goal is to confirm the drug's safety and effectiveness outside of clinical trials.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.